Alkem Laboratories
- Market cap
- ₹ 58,966 Cr.
- P/E
- 26.7x
- P/B
- 4.34x
- 52-week range
- 4,811 – 5,933.5
- ROE
- 19%
- ROCE
- 21%
- Dividend yield
- 1.1%
- Debt / equity
- 0.15
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Alkem Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)26.7 against a typical 34.3: cheaper than most peers (1st = cheapest).86th of 220
- Sales growth+10.9% against a typical +15.6% from a year earlier.112th of 197
- Profit growth−22% against a typical +18.9% from a year earlier.116th of 160
- Share price, 3 months−10.6% against a typical −0.5%.148th of 200
- Size₹ 58,966.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).11th of 199
Latest announcements
Exchange filings and their impact on the company.
- Alkem ordered a forensic audit into alleged fund misappropriation by a former employee; financial hit looks small but adds governance overhang.
On 21 October 2026, Alkem Laboratories said its Audit Committee approved a forensic audit into alleged misappropriation of funds by a former employee to examine facts, find root cause and recommend corrective action. No amount, period or business unit was disclosed. The proactive review should contain any loss to a likely small one-off, but it creates a near-term governance overhang until findings are published.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA+ by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil AA+ | Stable | 8 Jul 2026 |
| India Ratings | — | — | 6 Feb 2026 |
| CARE | CARE AA+ / CARE A1+ | Stable | 5 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 Jul 2026 | Reaffirmed | Crisil AA+ | — | CRISIL | ₹ 750 Cr. | |
| 24 Feb 2026 | Reaffirmed | Crisil AA+ | — | CRISIL | ₹ 725 Cr. | |
| 6 Feb 2026 | Reaffirmed | — | — | India Ratings | ₹ 500 Cr. | |
| 5 Jan 2026 | Reaffirmed | CARE AA+ / CARE A1+ | — | CARE | ₹ 300 Cr. | |
| 15 Sep 2025 | Reaffirmed | Crisil AA+ | — | CRISIL | ₹ 725 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results | Notice of meeting of the Board of Directors of Alkem Laboratories Limited ( the Company ) |
| 28 May 2026 | Financial Results/Dividend | Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 28th May, 2026, inter alia:(i) To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2026; and (ii) To consider and recommend Final Dividend, if any, for financial year ended 31st March, 2026. |
| 13 Feb 2026 | Financial Results/Dividend | Notice of meeting of the Board of Directors of Alkem Laboratories Limited ( the Company ) |
| 13 Nov 2025 | Financial Results | Notice of meeting of the Board of Directors of the Company scheduled to be held on Thursday, 13th November, 2025, inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2025. |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 29 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and final dividend, if any |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Expenses | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 |
| Operating Profit | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% |
| Other Income | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net Profit | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS in Rs | 51.9 | 49.76 | 24.55 | 45.6 | 57.6 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 | 43.49 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 12%
- 5 Years
- 11%
- 3 Years
- 8%
- TTM
- 13%
- 10 Years
- 12%
- 5 Years
- 9%
- 3 Years
- 32%
- TTM
- 0%
- 10 Years
- 13%
- 5 Years
- 7%
- 3 Years
- 12%
- TTM
- —
- 10 Years
- 18%
- 5 Years
- 18%
- 3 Years
- 19%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Alkem Laboratories | ₹ 5,070.00 | ₹ 58,966 Cr. | 26.7x | 4.3x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Basudeo Narain Singh
- Executive Chairman of the Board
- Nitin Agrawal
- President - Finance, Chief Financial Officer
- Manish Narang
- President - Legal, Compliance Officer, Company Secretary
- Sandeep Singh
- Managing Director, Executive Director
- Madhurima Singh
- Executive Director
- Mritunjay Kumar Singh
- Executive Director
- Sarvesh Singh
- Executive Director
- Srinivas Singh
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.